Clinica Oncologica, Università Politecnica delle Marche - AOU Ospedali Riuniti, Ancona, Italy.
Eur Rev Med Pharmacol Sci. 2022 Jul;26(13):4659-4665. doi: 10.26355/eurrev_202207_29188.
The Italian Association for Medical Oncology (AIOM) recommends preventive treatment of skeletal-related events in order to improve survival and the quality of life of patients with advanced malignancies. The aim of the study was to evaluate whether routine clinical practice is in agreement with recommendations about the use of denosumab.
A survey was carried out in Italy in the oncological setting.
The answers to the survey showed that a large proportion of patients with metastases from solid tumors receive treatment; almost all oncologists administered denosumab every 4 weeks but for a shorter period of time than recommended.
This survey showed that Italian oncologists favor the use of bone-targeted therapy to prevent skeletal-related events in patients affected by metastatic breast, prostate or lung cancer, in agreement with current recommendations.
意大利肿瘤医学协会（AIOM）建议对骨骼相关事件进行预防性治疗，以改善晚期恶性肿瘤患者的生存和生活质量。本研究旨在评估常规临床实践是否符合使用地舒单抗的建议。
在意大利肿瘤学环境中进行了一项调查。
调查结果显示，很大一部分患有实体瘤转移的患者接受了治疗；几乎所有的肿瘤学家都每 4 周给予地舒单抗，但用药时间短于推荐的时间。
这项调查显示，意大利肿瘤学家倾向于使用骨靶向治疗来预防转移性乳腺癌、前列腺癌或肺癌患者的骨骼相关事件，这与当前的建议一致。
